Edition:
United States

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

9.48USD
16 Feb 2018
Change (% chg)

$-0.44 (-4.44%)
Prev Close
$9.92
Open
$9.88
Day's High
$10.40
Day's Low
$9.46
Volume
111,314
Avg. Vol
74,748
52-wk High
$15.65
52-wk Low
$7.43

Latest Key Developments (Source: Significant Developments)

Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca
Thursday, 1 Feb 2018 07:00am EST 

Feb 1 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA.SYNDAX PHARMACEUTICALS INC - CO & ASTRAZENECA TO COLLABORATE ON NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN MULTIPLE SOLID TUMOR TYPES.SYNDAX PHARMACEUTICALS INC - SYNDAX EXPECTS TO INITIATE A PHASE IB STUDY IN FIRST HALF OF 2018.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 07:00am EST 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 07:53am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

Syndax Pharmaceuticals Q2 loss per share $0.70
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Syndax Pharmaceuticals Inc :Syndax Pharmaceuticals reports second quarter 2017 financial results and provides clinical and business update.Q2 loss per share $0.70.Q2 earnings per share view $-0.83 -- Thomson Reuters I/B/E/S.Syndax Pharmaceuticals Inc - ‍for Q3 research and development expenses are expected to be $12.0 to $14.0 million​.Syndax Pharmaceuticals Inc - ‍for full year 2017, research and development expenses are expected to be $46.0 to $51.0 million​.  Full Article

Syndax prices public offering of common stock
Wednesday, 24 May 2017 08:05pm EDT 

May 24 (Reuters) - Syndax Pharmaceuticals Inc :Syndax prices public offering of common stock.Pricing of an underwritten public offering of 3.7 million shares of its common stock at a price to public of $13.25 per share.  Full Article

Syndax Pharma to offer common stock in public offering
Tuesday, 23 May 2017 04:48pm EDT 

May 23 (Reuters) - Syndax Pharmaceuticals Inc :Syndax announces proposed public offering of common stock.Syndax pharmaceuticals inc- it plans to offer and sell $50 million of its common stock in an underwritten public offering.  Full Article

Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda
Wednesday, 17 May 2017 05:07pm EDT 

May 17 (Reuters) - Syndax Pharmaceuticals Inc :Syndax announces results from phase 2 ENCORE 601 trial of entinostat in combination with Keytruda (pembrolizumab) for the treatment of advanced melanoma.31% objective response rate for first stage of phase 2 melanoma cohort of ENCORE 601.ENCORE 601 now enrolling expanded cohorts of melanoma and NSCLC patients progressed on or after anti-PD1 therapies.  Full Article

Syndax Pharmaceuticals announces advancement of encore 601
Tuesday, 16 May 2017 05:26pm EDT 

May 16 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals announces advancement of encore 601 in non-small cell lung cancer patients with disease progression on or after PD-1 therapies.Syndax Pharmaceuticals Inc - cohort of NSCLC patients who had previously progressed on PD-1 or PD-l1 will now re-open and enroll a total of 56 patients.Syndax Pharmaceuticals Inc- completion of enrollment is anticipated in first half of 2018 for study.Syndax Pharmaceuticals - later this quarter, co anticipates being able to determine whether to expand cohort of NSCLC patients naïve to PD-1 or PD-l1 therapy.Syndax-Encore 601 non-small cell lung cancer study has met pre-specified objective response threshold to advance into 2nd stage of phase 2 trial.  Full Article